CTCF-related disorder (CRD) is a multisystem neurodevelopmental condition caused by monoallelic (heterozygous) pathogenic variants in the CTCF gene. The gene encodes a highly conserved zinc-finger protein essential for 3D genome architecture and transcriptional regulation. In humans, CTCF is intolerant to germline variation, and loss of one functional copy leads to disease, highlighting haploinsufficiency as the primary mechanism.
Affected individuals most often present with the following core clinical features:
• Global developmental delay or intellectual disability
• Microcephaly
• Short stature or failure to thrive
• Low muscle tone (hypotonia) and early feeding challenges
• Distinct craniofacial characteristics
• Behavioral traits, including autism spectrum disorder
Additional findings may include congenital anomalies of the heart, genitourinary tract, and musculoskeletal system, reflecting the broad phenotypic spectrum associated with CRD.
CRD results from heterozygous pathogenic variants in CTCF. To date, over 160 distinct germline variants—comprising single-nucleotide changes, frameshifts, nonsense mutatioover 160 distinct germline variants been reported in individuals with neurodevelopmental phenotypes. Most cases arise from de novo mutations.
The prevalence of CRD is still being determined. As the use of high-throughput genomic testing expands in neurodevelopmental cohorts, novel CTCF variants continue to emerge—86 additional pathogenic variants were identified beyond those reported in prior literature through genotype–phenotype database mining. CRD shows variable expressivity, and penetrance remains poorly understood.
Inheritance: Autosomal dominant, primarily due to germline de novo variants; rare familial cases confirm the potential for inheritance.
Prevalence: Unknown; increasing with exome/genome sequencing uptake.
VUS: Many CTCF variants identified in individuals with neurodevelopmental phenotypes are classified as variants of uncertain significance (VUS) and are particularly common for variants that lie outside well-characterized functional domains (such as the zinc finger DNA-binding domains) or for which no functional data yet exist. It is important to recognize that some VUS may ultimately prove pathogenic as functional studies and clinical correlations evolve, while others may be benign. Ongoing research—including variant modelling, patient-derived cellular studies, and careful phenotype–genotype correlation—is needed to resolve the significance of VUS in CTCF and improve variant interpretation in clinical genetics. Please contact the moderator for questions regarding the potential pathogenicity of specific VUS.
CTCF